Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab (Yervoy) and dacarbazine were alive after four years compared with patients who received dacarbazine alone, suggesting that ipilimumab has long-term survival benefits and that the combination could serve as an effective treatment regimen.

The results of the long-term follow-up were presented at the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria.

Ipilimumab, which is administered intravenously, is a monoclonal antibody that blocks the cytotoxic T-lymphocyte antigen (CTLA-4) molecule. CTLA-4 is implicated in suppressing antitumor immune responses. Dacarbazine is a triazene derivative with antineoplastic activity. Both drugs are approved to treat metastatic melanoma. Read More...

Melanoma Research Foundation

Donate Today

Every day the Melanoma Research Foundation works to make the fight against melanoma easier.
Your donation will help us support patients, fund research and advocate for the melanoma community.